OptimizeRx Corp Quarterly Net Cash Provided by (Used in) Financing Activities in USD from Q1 2013 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
OptimizeRx Corp quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from Q1 2013 to Q1 2024.
  • OptimizeRx Corp Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2024 was -$640K, a 389% decline year-over-year.
  • OptimizeRx Corp annual Net Cash Provided by (Used in) Financing Activities for 2023 was $28.2M.
  • OptimizeRx Corp annual Net Cash Provided by (Used in) Financing Activities for 2022 was -$19M, a 126% decline from 2021.
  • OptimizeRx Corp annual Net Cash Provided by (Used in) Financing Activities for 2021 was $73.9M.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$640K -$509K -389% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q1 2023 -$131K -$389K -151% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q1 2022 $258K -$69.9M -99.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-12
Q1 2021 $70.2M +$70.1M +62476% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q1 2020 $112K -$232K -67.4% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q1 2019 $344K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-06
Q1 2016 -$357K Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-03
Q1 2014 $2.8M +$2.8M Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-14
Q1 2013 $0 Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.